

REMARKS

The claims have been restricted into the following two groups:

Group I, claims 1-14, drawn to a pharmaceutical composition comprising interferon beta, classified in class 424, subclass 85.6.; and

Group II, claims 15-16, drawn to a method for treating a patient for multiple sclerosis comprising administering to said patient the pharmaceutical composition, classified in class 514, subclass 12.

Applicants elect Group II, claims 15-16, with traverse. Applicants traverse the requirement on the grounds that the search and examination of the two groups of claims is not unduly burdensome.

Applicants now await early and favorable action on the merits. The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Conclusion

The present application is now in condition for allowance. The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Atty. Dkt. No. 073259-0105
Appln. No. 10/815,342

Respectfully submitted,

Date Dec 13 2006

By Michele M. Simkin

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5538
Facsimile: (202) 672-5399

Michele M. Simkin
Attorney for Applicants
Registration No. 34,717